Global Scleroderma Therapeutics Market Report 2023: Availability of a Range of Treatment Options Drives Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Scleroderma Therapeutics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

The value of the global scleroderma therapeutics market was USD 1.92 billion in 2022, driven by increasing prevalence of scleroderma, rising awareness about the disease across the globe. The market is expected to grow at a CAGR of 6.20% during the forecast period of 2023-2031 to reach value of USD 3.29 billion by 2031.

Scleroderma, also known as systemic sclerosis, is a rare autoimmune disease that affects the skin and internal organs. The disease is characterized by excessive production and deposition of collagen in various tissues, leading to thickening, hardening, and scarring. Scleroderma can affect different parts of the body, including the skin, lungs, kidneys, heart, and digestive system. The disease is chronic and progressive, and there is currently no cure. However, several treatments are available to manage symptoms and slow down the progression of the disease.

The global scleroderma therapeutics market is driven by the increasing prevalence of scleroderma, rising awareness about the disease, and the availability of a range of treatment options. The market is also supported by the growing investment in research and development activities to discover new drugs and therapies for scleroderma. However, the high cost of treatment and the limited availability of effective therapies in some regions may hinder market growth.

Scleroderma Therapeutics Application and Uses

Scleroderma is a rare autoimmune disease that affects the skin and other organs of the body. There is no cure for scleroderma, but treatment can help manage its symptoms and complications. Some of the commonly used therapies for scleroderma include:

• Immunosuppressive drugs: Drugs that suppress the immune system can help to reduce inflammation and slow down the progression of scleroderma. Some examples include methotrexate, mycophenolate mofetil, and cyclophosphamide
• Anti-inflammatory drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin can help to reduce pain and inflammation
• Blood pressure medications: Drugs that dilate blood vessels can help to improve blood flow to the affected areas of the body. Some examples include calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors
• Skin moisturizers: Moisturizers and creams can help to soften and hydrate the skin, reducing the severity of skin symptoms
• Physical therapy: Exercises and stretching can help to maintain flexibility and range of motion in the affected joints and muscles
• Occupational therapy: Occupational therapy can help individuals with scleroderma to manage daily activities and maintain their independence
• Pulmonary rehabilitation: Pulmonary rehabilitation can help individuals with scleroderma to manage lung-related symptoms and improve their breathing
• Surgery: In severe cases, surgery may be required to treat complications such as digital ulcers or lung disease
• Stem cell transplant: Stem cell transplant is an experimental therapy that involves replacing the patient's bone marrow with healthy stem cells to rebuild the immune system

The choice of treatment depends on the severity of the disease and the specific symptoms experienced by the individual. In some cases, a combination of therapies may be required to manage the symptoms and slow down the progression of scleroderma.

Key Players

The report gives an in-depth analysis of the key players involved in the global scleroderma therapeutics market. The companies included in the market are as follows:

• F. Hoffman-La Roche Ltd
• Boehringer Ingelheim International GmbH
• arGentisT Pharmaceuticals, LLS
• Kadmon Holdings, Inc
• Emerald Health Pharmaceuticals Inc
• EuBiologics Co., Ltd
• Astellas Pharma Inc
• Sanofi
• Allergan
• Novartis AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc

Market Segmentation

by Drug Class

• Immunosuppressors
• Phosphodiesterase 5 Inhibitors - PHA
• Endothelin Receptor Antagonists
• Prostacyclin Analogues
• Calcium Channel Blockers
• Analgesics
• Others

by Indication

• Systemic
• Localized

by Treatment Type

• Drug Treatment
• Surgical Treatment
• Therapy

by End User

• Hospitals and Clinics
• Homecare Settings
• Others

by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

For more information about this report visit https://www.researchandmarkets.com/r/e23lr9

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.